While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.

First-line non-small cell lung cancer (NSCLC )is a highly competitive disease setting, and near-term readouts across several programs will shape the NSCLC treatment landscape. Image credit: [Near D Krasaesom]/Shutterstock.com

Several abstracts and data presentations on emerging clinical research in non-small cell lung cancer prompted expert interest and discussion at the American Society of Clinical Oncology (ASCO) 2026, held 29 May–2 June, 2026.

Here is a look at the potential impact of two such presentations; one focused on the Akeso and Summit Therapeutics’ PD-1/VEGF-targeting bispecific antibody ivonescimab, and another focused on the efficacy of Eli Lilly’s RET-targeting tyrosine kinase inhibitor Retvemo (selpercatinib).

Akeso and Summit demonstrate a significant reduction in death for ivonescimab